학술논문

LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Document Type
Abstract
Source
In Annals of Oncology September 2020 31 Supplement 4:S1173-S1174
Subject
Language
ISSN
0923-7534